NYSE · CIK 0001337298
FF FutureFuel Corp.
Insider trading from SEC Form 4. Last filing Jun 5, 2026. Close $5.22 on Oct 9, 2026, +75% from the 52-week low and -18% from the high.
FutureFuel Corp. (FF) has 34 SEC Form 4 filings on file from 12 insiders, the latest filed on Jun 5, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
7 open-market trades have been scored at FF. The newest: Roeland Polet (Chief Executive Officer) bought $43k of stock on Jun 4, 2026, filed Jun 5, 2026, scored 37 (weak). The largest of the 7 shown: Richard P. Rowe (director) bought $59k on Apr 3, 2025, scored 58 (moderate). 2 insiders bought within 14 days of each other around Apr 3, 2025.
FF closed at $5.22 on Oct 9, 2026, 75% above its 52-week low and 18% below its 52-week high.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at FutureFuel Corp., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 37Weak | Roeland Polet Chief Executive Officer buy | $43k 10,000 shares | +40% | +46% from low-12% from high | |
| 60Notable | Roeland Polet Chief Executive Officer buy | $48k 15,000 shares | +150% | +1% from low-42% from high | |
| 58Moderate | Richard P. Rowe director buy | $59k 15,000 shares | +300% | +4% from low-34% from high | |
| 50Moderate | Donald C. Bedell director buy | $40k 10,000 shares | +10% | +4% from low-34% from high | |
| 58Moderate | Richard P. Rowe director buy | $59k 15,000 shares | +300% | +4% from low-34% from high | |
| 33Weak | Donald C. Bedell director buy | $51k 10,000 shares | +11% | - | |
| 48Moderate | Roeland Polet Chief Executive Officer buy | $51k 10,000 shares | - | - |
Transactions
Every row filed, 34 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 4, 2026 | Roeland Polet Chief Executive Officer | POpen-market purchase Common Stock | +10,000 | $4.28 | $43k | 35,000 | Jun 5, 2026 |
| Mar 18, 2026 | Donald C. Bedell director | AGrant or award Stock Options (Right to Buy)derivative | +10,000 | $0.00 | $0 | 10,000 | Mar 19, 2026 |
| Mar 18, 2026 | Ronald J Kruszewski director | AGrant or award Stock Options (Right to Buy)derivative | +10,000 | $0.00 | $0 | 10,000 | Mar 19, 2026 |
| Mar 18, 2026 | Richard P. Rowe director | AGrant or award Stock Options (Right to Buy)derivative | +10,000 | $0.00 | $0 | 10,000 | Mar 19, 2026 |
| Mar 18, 2026 | Paul Manheim director | AGrant or award Stock Options (Right to Buy)derivative | +10,000 | $0.00 | $0 | 10,000 | Mar 19, 2026 |
| Mar 18, 2026 | Paul Anthony Novelly II director | AGrant or award Stock Options (Right to Buy)derivative | +10,000 | $0.00 | $0 | 10,000 | Mar 19, 2026 |
| Mar 18, 2026 | GBruce Greer director | AGrant or award Stock Options (Right to Buy)derivative | +10,000 | $0.00 | $0 | 10,000 | Mar 19, 2026 |
| Mar 18, 2026 | Dale E Cole director | AGrant or award Stock Options (Right to Buy)derivative | +10,000 | $0.00 | $0 | 10,000 | Mar 19, 2026 |
| Mar 18, 2026 | Pamela R Butcher director | AGrant or award Stock Options (Right to Buy)derivative | +10,000 | $0.00 | $0 | 10,000 | Mar 19, 2026 |
| Dec 11, 2025 | Kyle Gaither Chief Operations Officer | AGrant or award Common Stock | +5,012 | $0.00 | $0 | 6,173 | Dec 15, 2025 |
| Dec 11, 2025 | Rose Sparks Chief Financial Officer | AGrant or award Common Stock | +5,012 | $0.00 | $0 | 24,295 | Dec 15, 2025 |
| Nov 18, 2025 | Donald C. Bedell director | AGrant or award Common Stock | +5,000 | $0.00 | $0 | 10,000 | Nov 25, 2025 |
| Nov 18, 2025 | Pamela R Butcher director | AGrant or award Common Stock | +5,000 | $0.00 | $0 | 5,000 | Nov 25, 2025 |
| Nov 18, 2025 | Dale E Cole director | AGrant or award Common Stock | +5,000 | $0.00 | $0 | 11,350 | Nov 25, 2025 |
| Nov 18, 2025 | Paul Manheim director | AGrant or award Common Stock | +5,000 | $0.00 | $0 | 29,103 | Nov 25, 2025 |
| Nov 20, 2025 | Roeland Polet Chief Executive Officer | POpen-market purchase Common Stock | +15,000 | $3.20 | $48k | 25,000 | Nov 24, 2025 |
| Nov 18, 2025 | Paul Anthony Novelly II director, owner | AGrant or award Common Stock | +5,000 | $0.00 | $0 | 10,000 | Nov 20, 2025 |
| Nov 18, 2025 | Richard P. Rowe director | AGrant or award Common Stock | +5,000 | $0.00 | $0 | 25,000 | Nov 20, 2025 |
| Nov 18, 2025 | GBruce Greer director | AGrant or award Common Stock | +5,000 | $0.00 | $0 | 10,000 | Nov 20, 2025 |
| Nov 18, 2025 | Ronald J Kruszewski director | AGrant or award Common Stock | +5,000 | $0.00 | $0 | 10,000 | Nov 20, 2025 |
| Apr 3, 2025 | Richard P. Rowe director | POpen-market purchase common stock | +15,000 | $3.95 | $59k | 20,000 | May 7, 2025 |
| Apr 3, 2025 | Donald C. Bedell director | POpen-market purchase Common Stockindirect: Note 1 | +10,000 | $4.00 | $40k | 109,975 | Apr 4, 2025 |
| Apr 3, 2025 | Richard P. Rowe director | POpen-market purchase Common Stock | +15,000 | $3.95 | $59k | 20,000 | Apr 4, 2025 |
| Apr 3, 2025 | Pamela R Butcher director | AGrant or award Stock Options (Right to Buy)derivative | +10,000 | $0.00 | $0 | 10,000 | Apr 3, 2025 |
| Dec 5, 2024 | Donald C. Bedell director | AGrant or award Common Stock | +5,000 | $0.00 | $0 | 5,000 | Dec 9, 2024 |
| Dec 5, 2024 | Dale E Cole director | AGrant or award Common Stock | +5,000 | $0.00 | $0 | 6,350 | Dec 9, 2024 |
| Dec 5, 2024 | Terrance C Z Egger director | AGrant or award Common Stock | +5,000 | $0.00 | $0 | 14,895 | Dec 9, 2024 |
| Dec 5, 2024 | GBruce Greer director | AGrant or award Common Stock | +5,000 | $0.00 | $0 | 5,000 | Dec 9, 2024 |
| Dec 5, 2024 | Paul Anthony Novelly II director, owner | AGrant or award Common Stock | +5,000 | $0.00 | $0 | 5,000 | Dec 9, 2024 |
| Dec 5, 2024 | Paul Manheim director | AGrant or award Common Stock | +5,000 | $0.00 | $0 | 24,103 | Dec 9, 2024 |
| Dec 5, 2024 | Ronald J Kruszewski director | AGrant or award Common Stock | +5,000 | $0.00 | $0 | 5,000 | Dec 9, 2024 |
| Dec 5, 2024 | Richard P. Rowe director | AGrant or award Common Stock | +5,000 | $0.00 | $0 | 5,000 | Dec 9, 2024 |
| Nov 15, 2024 | Donald C. Bedell director | POpen-market purchase Common Stockindirect: Note 1 | +10,000 | $5.10 | $51k | 99,975 | Nov 19, 2024 |
| Nov 13, 2024 | Roeland Polet Chief Executive Officer | POpen-market purchase Common Stock | +10,000 | $5.11 | $51k | 10,000 | Nov 13, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Donald C. Bedelldirector
- Pamela R Butcherdirector
- Dale E Coledirector
- Terrance C Z Eggerdirector
- Kyle GaitherChief Operations Officer
- GBruce Greerdirector
- Ronald J Kruszewskidirector, ceo, officer
- Paul Manheimdirector
- Paul Anthony Novelly IIdirector, owner
- Roeland PoletChief Executive Officer
- Richard P. Rowedirector
- Rose SparksChief Financial Officer
Questions about FF
Answered from the filings on this page, as of the latest one.
Are insiders buying FF?
No. In the last 90 days no insider at FutureFuel Corp. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade FF on the open market?
Roeland Polet (Chief Executive Officer) bought $43k of FF on Jun 4, 2026 and filed the Form 4 on Jun 5, 2026. InsiderTell scored 37 (weak).
How many insiders file Form 4 at FutureFuel Corp.?
12 people have filed a Form 4 at FutureFuel Corp., among them Donald C. Bedell (director), Pamela R Butcher (director), Dale E Cole (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.